HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.
Stocks · News reference
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target
Reported Earlier, Arrowhead Reports Plozasiran Also Reduced Pancreatitis Risk In Severe Triglyceride Patients
Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology Congress
Why Biohaven Stock Was Rocking the Market This Week
Biohaven announced a licensing and collaboration deal with SK Biopharmaceuticals worth up to $795 million for exclusive worldwide rights to its Kv7 ion channel platform and lead drug candidate opakalim for focal epilepsy treatment. Additionally, Biohaven and Yale University won a $4 million judgment in a trade secret misappropriation lawsuit against Avilar Therapeutics and RA Capital Management. These developments drove Biohaven stock up more than 16% week-to-date.
Why Is Biohaven Stock Soaring Wednesday?
Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair eyes upcoming trial data.